Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial

This publication has 21 references indexed in Scilit:

• Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT
  Frontiers in Immunology, 2019
• Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis
  British Journal of Haematology, 2019
• Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
  Blood, 2019
• Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
  Haematologica, 2016
• Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry
  Journal of Korean Medical Science, 2016
• Thrombosis in paroxysmal nocturnal hemoglobinuria
  Blood, 2013
• Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria
  American Journal of Hematology, 2010
• Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
  Blood, 2008
• The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
  New England Journal of Medicine, 2006
• Natural History of Paroxysmal Nocturnal Hemoglobinuria
  New England Journal of Medicine, 1995